Skip to content
drillr.ai
Sign up

VYNE

VYNE Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$28.56
+0.00%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue955.0K570.0K501.0K424.0K477.0K
Cost of Revenue6.0K23.0K———
Gross Profit949.0K547.0K501.0K424.0K477.0K
Operating Expenses
R&D Expense28.3M19.2M30.9M16.3M18.4M
SG&A Expense19.2M11.1M13.2M13.4M16.4M
General & Admin Expense19.2M11.1M13.2M13.4M16.4M
Selling & Marketing Expense—————
Other Expenses—(23.0K)———
Total Operating Expenses47.5M30.3M44.1M29.7M34.8M
Cost and Expenses47.5M30.3M44.1M29.7M34.8M
Operating Income (EBIT)(46.6M)(29.7M)(43.6M)(29.3M)(34.3M)
Non-Operating
Interest Income—————
Interest Expense—————
Net Interest Income—————
Other Non-Op Income/Expense3.9M3.0M3.8M1.4M363.0K
Non-Operating Income (excl Interest)(860.0K)(3.0M)(3.8M)(1.4M)(363.0K)
EBT (Pre-Tax Income)(42.7M)(26.7M)(39.8M)(27.9M)(33.9M)
Income Tax Expense8.0K4.0K4.0K—13.0K
Bottom Line
Net Income(42.2M)(26.5M)(39.8M)(28.5M)(23.2M)
Earnings from Cont. Ops(42.7M)(26.7M)(39.8M)(27.9M)(33.9M)
Earnings from Discont. Ops522.0K253.0K(27.0K)(580.0K)10.7M
Bottom Line Net Income(42.2M)(26.5M)(39.8M)(28.5M)(23.2M)
Per Share
Basic EPS($636.98)($31.00)($47.00)($138.50)($532.50)
Diluted EPS($636.98)($31.00)($47.00)($138.50)($532.50)
Revenue Per Share$22.33$0.67$0.59$2.06$7.49
Shares
Basic Shares Outstanding4276885536085178020546063719
Diluted Shares Outstanding4276885536085178020546063719
Profitability Metrics
EBITDA(45.7M)(26.7M)(39.8M)(27.9M)(33.9M)
D&A17.0K—4.0K—72.0K
EBIT(45.7M)(26.7M)(39.8M)(27.9M)(33.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026